Aromatase Inhibition and Capecitabine Combination as 1<sup>st</sup> or 2<sup>nd</sup> Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis

Shankar, Abhishek; Roy, Shubham; Rath, Goura Kishor; Julka, Pramod Kumar; Kamal, Vineet Kumar; Malik, Abhidha; Patil, Jaineet; Jeyaraj, Pamela Alice; Mahajan, Manmohan K

추천

검색

자료유형: 학술저널

저자정보: Shankar, Abhishek (Department of Radiation Oncology, Dr. B.R.Ambedkar Institute Rotary Cancer Hospital) Roy, Shubham (Department of Paediatrics, VMMC and Safdarjung Hospital) Rath, Goura Kishor (Department of Radiation Oncology, Dr. B.R.Ambedkar Institute Rotary Cancer Hospital) Julka, Pramod Kumar (Department of Radiation Oncology, Dr. B.R.Ambedkar Institute Rotary Cancer Hospital) Kamal, Vineet Kumar (Department of Bio-Statistics, All India Institute of Medical Sciences) Malik, Abhidha (Department of Radiation Oncology, Dr. B.R.Ambedkar Institute Rotary Cancer Hospital) Patil, Jaineet (Department of Radiation Oncology, Christian Medical College) Jeyaraj, Pamela Alice (Department of Radiation Oncology, Christian Medical College) Mahajan, Manmohan K (Department of Radiation Oncology, Christian Medical College)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제16권 제15호

발행연도: 2015.1

수록면: 6,359 - 6,364 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Preclinical studies have shown that the combination of an aromatase inhibitor (AI) and capecitabine in estrogen receptor (ER)- positive cell lines enhance antitumor efficacy. This retrospective analysis of a group of patients with metastatic breast cancer (MBC) evaluated the efficacy and safety of combined AI with capecitabine. Materials and Methods: Patients with hormone receptor-positive metastatic breast cancer treated between 1st January 2005 and 31st December 2010 with a combination of capecitabine and AI were evaluated and outcomes were compared with those of women treated with capecitabine in conventional dose or AI as a monotherapy. Results: Of 72 patients evaluated, 31 received the combination treatment, 22 AI and 19 capecitabine. The combination was used in 20 patients as first-line and 11 as second-line treatment. Mean age was 46.2 years with a range of 28-72 years. At the time of progression, 97% had a performance status of <2 and 55% had visceral disease. No significant difference was observed between the three groups according to clinical and pathological features. Mean follow up was 38 months with a range of 16-66 months. The median PFS of first-line treatment was significantly better for the combination (PFS 21 months vs 8.0 months for capecitabine and 15.0 months for AI). For second-line treatment, the PFS was longer in the combination compared with capecitabine and Al groups (18 months vs. 5.0 months vs. 11.0 months, respectively). Median 2 year and 5 year survival did not show any significant differences among combination and monotherapy groups. The most common adverse events for the combination group were grade 1 and 2 hand-for syndrome (69%), grade 1 fatigue (64%) and grade 1 diarrhoea (29%). Three grade 3 hand-foot syndrome events were reported. Conclusions: Combination treatment with capecitabine and AI used as a first line or second line treatment was safe with much lowered toxicity. Prospective randomized clinical trials should evaluate the use of combination therapy in advanced breast cancer to confirm these findings.

#Aromatase inhibitors #capecitabine #metastatic breast cancer

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

Shankar, Abhishek

소속기관 Department of Radiation Oncology, Dr. B.R. Ambedkar Institute Rotary Cancer Hospital, Maulana Azad M